In the last trading session, 3.78 million Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) shares changed hands as the company’s beta touched 0.39. With the company’s per share price at $0.47 changed hands at $0.03 or 6.09% during last session, the market valuation stood at $32.94M. BCLI’s last price was a discount, traded about -519.15% off its 52-week high of $2.91. The share price had its 52-week low at $0.13, which suggests the last value was 72.34% up since then. When we look at Brainstorm Cell Therapeutics, Inc.’s average trading volume, we note the 3-month average coming to 899.01K.
Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) trade information
Instantly BCLI was in green as seen at the end of in last trading. With action 14.33%, the performance over the past five days has been green. The jump to weekly highs of 0.5390 added 6.09% to the stock’s daily price. The company’s shares are showing year-to-date upside of 72.16%, with the 5-day performance at 14.33% in the green. However, in the 30-day time frame, Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) is -2.89% down.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Brainstorm Cell Therapeutics, Inc. (BCLI) estimates and forecasts
Data shows that the Brainstorm Cell Therapeutics, Inc. share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 125.64% over the past 6 months, a 45.10% in annual growth rate that is considerably higher than the industry average of 15.60%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 10.57%. The 2024 estimates are for Brainstorm Cell Therapeutics, Inc. earnings to increase by 67.50%.
BCLI Dividends
Brainstorm Cell Therapeutics, Inc. is expected to release its next quarterly earnings report in July.
